Canbiola Reports Third Quarter 2019 Results


Ryan Allway

November 20th, 2019

News


 

Revenue Growth of 277% Demonstrates Successful Traction in the Medical Community; Gross Margin of 77%

HICKSVILLE, NY, Nov. 20, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Canbiola, Inc. (OTCQBCANB) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of hemp-derived THC-Free Cannabidiol (CBD) Isolate products such as oils, drops/tinctures, creams, moisturizers, chews, and capsules, announced today the company’s financial results for the third quarter ended September 30, 2019.

Key Financial Highlights for Q3 2019:

  • Revenues increased by 277% from the three months ended September 30, 2018, to $615,422
  • Gross margin of 77% for three months ended September 30, 2019
  • Operating loss of $935,264, included $602,823 in non-cash stock-based compensation

Key Business Highlights for Q3 2019:

  • Closed on joint venture with NY SHI and Shi Farms to operate NY Hemp Depo’s Facility
  • Launched dedicated Canbiola-branded CBD dispensing machine

Management Commentary

“We are very pleased with our third quarter results as we continue to ramp our business across all of our brands, with Pure Leaf Oil and Seven Chakras targeting consumers through retail and internet channels and the Canbiola brand and product line focused on marketing through the medical professionals’ market,” commented Marco Alfonsi, Canbiola’s Chief Executive Officer. “Our 277% year-over-year revenue growth is reflective of our increasing traction with existing and new customers and sales channels. Our high gross margins of 77% demonstrate our ability to efficiently source and manufacture our ingredients and formulations.”

Mr. Alfonsi concluded, “Our all-natural ingredients and state-of-the-art processing and packaging equipment in a “clean room” environment add to the product quality story of the company. Our portfolio of 120+ products span oils, creams, moisturizers, chews, gel caps, bath bombs, massage oils, and concentrate continue to lead the way in the CBD category. We look forward to continuing to communicate our business progress.”

Financial Results for the Three Months Ended September 30, 2019:

Revenue for the three months ended September 30, 2019, was $615,422, an increase of $452,094 or 277%, compared to $163,328 for the three months ended September 30, 2018.

Gross profit for the three months ended September 30, 2019, was $473,572, an increase of $399,882 or 543%, compared to $73,690 for the three months ended September 30, 2018. The resulting gross margin was 76.9% for the three months ended September 30, 2019, compared to 45.1% for the three months ended September 30, 2018.

Operating expenses for the three months ended September 30, 2019 were $1,408,836, an increase of $668,233 or 90%, compared to $740,603 for the three months ended September 30, 2018. For the three months ended September 30, 2019, operating expenses included non-cash stock-based compensation of $602,823 paid to officers, employees, and service of consultants, compared to $518,317 for the three months ended September 30, 2018.

Operating loss for the three months ended September 30, 2019 was $935,264, an increase of $268,351, or 40%, compared to $666,913 for the three months ended September 30, 2018.

Adjusted operating loss for the three months ended September 30, 2019 was $332,441, an increase of $183,845, or 124%, compared to $148,596 for the three months ended September 30, 2018. Adjusted operating loss does not include non-cash stock-based compensation.

Net loss for the three months ended September 30, 2019, was $941,099, a decrease of $3,214,600, or 77%, compared to $4,155,699 for the three months ended September 30, 2018. The resulting EPS loss for the three months ended September 30, 2019 was ($0.00) per diluted share, compared to ($0.00) per diluted share for the three months ended September 30, 2018.

Financial Results for the Nine Months Ended September 30, 2019:

Revenue for the nine months ended September 30, 2019 was $1,766,161, an increase of $1,387,873 or 356%, compared to $387,288 for the nine months ended September 30, 2018.

Gross profit for the nine months ended September 30, 2019, was $1,062,554, an increase of $856,343 or 415%, compared to $206,211 for the nine months ended September 30, 2018. The resulting gross margin was 60.2% for the nine months ended September 30, 2019, compared to 53.2% for the nine months ended September 30, 2018.

Operating expenses for the nine months ended September 30, 2019 were $4,607,298, an increase of $2,631,048 or 133%, compared to $1,976,250 for the nine months ended September 30, 2018. For the nine months ended September 30, 2019, operating expenses included non-cash stock-based compensation of $2,390,967 paid to officers, employees, and service of consultants, compared to $1,276,493 for the nine months ended September 30, 2018.

Operating loss for the nine months ended September 30, 2019 was $3,544,744, an increase of $1,774,705, or 100%, compared to $1,770,039 for the nine months ended September 30, 2018.

Adjusted operating loss for the nine months ended September 30, 2019 was $1.153.777, an increase of $660,231, or 134%, compared to $493,546 for the nine months ended September 30, 2018. Adjusted operating loss does not include non-cash stock-based compensation.

Net loss for the nine months ended September 30, 2019, was $3,551,104, a decrease of $1,171,913, or 25%, compared to $4,723,017 for the nine months ended September 30, 2018. The resulting EPS loss for the nine months ended September 30, 2019 was ($0.00) per diluted share, compared to ($0.00) per diluted share for the nine months ended September 30, 2018.

About Canbiola, Inc.

Canbiola, Inc. (OTCQB: CANB) is a vertically integrated conglomerate specializing in the manufacturing, formulation, and sale of THC-Free Cannabidiol (CBD) Isolate products such as oils, drops/tinctures, gels, creams, moisturizers, chews, and capsules.  All Canbiola products are organic and Non-GMO, free of impurities and contaminants, and formulated with the finest ingredients to the highest manufacturing standards.  All products are certified for purity and accuracy by third-party laboratory verification.

Canbiola pursues an aggressive growth strategy through the continual development of proprietary products and the expansion of its offerings via strategic acquisitions in the healthcare and CBD industries.

Canbiola has created several innovative CBD product lines, marketed through targeted channels including:

The Canbiola clinical line, which is marketed and promoted through healthcare practitioners in the medical setting.

The Pure Leaf Oil (consumer brand) and Seven Chakras (spa brand) lines are sold through both online and brick & mortar retail outlets.

Canbiola’s state-of-the-art manufacturing facility in Lacey, WA is operated by Pure Health Products LLC (PHP), a wholly-owned subsidiary that produces all of the Company’s CBD Isolate products, in addition to providing private label and white label solutions for companies looking to add high-quality CBD items to their offerings. Canbiola is passionate about improving people’s lives and we take pride in providing pure CBD products infused with organic and natural ingredients. We want customers to know that they are buying lab-tested, high-quality natural products at a great price.

Canbiola’s Radical Tactical LLC subsidiary produces CBD products in other forms including vapes and gums.

Duramed Inc. and Duramed NJ LLC, wholly-owned subsidiaries of Canbiola, further the mission of providing innovative products designed to improve people’s lives, aiming to reduce their use of opioid substances through the utilization of durable medical devices. This product line includes a wearable low-intensity ultrasound SAM (Sustained Acoustic Medicine) device delivering multi-hour treatment intended to accelerate healing, improve function for musculoskeletal injuries (muscle, tendon, ligament) and reduce chronic pain (without opioid pain medication).

With the creation of its newest wholly owned subsidiary, NY Hemp Depot LLC, Canbiola has attained complete vertical integration, allowing it to fully control the supply chain from seed to sale, develop customized products and maximize profit margins. Through the utilization of its newly acquired NY State Hemp Cultivation License, the Company contracts with farmers throughout the state of NY to cultivate specific strains of hemp, which is then processed into CBD Isolate products to Canbiola’s exacting manufacturing standards and specifications at the Company’s laboratory and production facility.

For more information about Canbiola, Inc., please visit: Canbiola.com

Forward-Looking Statements

Forward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price. We undertake no responsibility to update forward-looking statements should actual results differ.

Follow Canbiola on:

Twitter @CanbiolaHealth

Instagram @canbiola.inc or @canbiola_cbd or @canbiola_medical_cbd

Investors and Media:

[email protected]

(516) 595-9544

Primary Logo

Made with pure hemp extract, Organic coconut oil and medium-chain-triglyceride (MCT)’s for maximum absorption and fast acting relief for a wide variety of health issues. Canbiola’s nano cannabinoid delivery system delivers over 450% more CBD action per milligram than using hemp by itself. Why? This is due to the extremely small particle size in Canbiola nano-drops and sprays combined with superior formulation of pure hemp extract and all-natural ingredients.

 

Ingredients: Pure Hemp extract (99% CBD), * Cocos Nucifera (Coconut Oil), * Coconut Medium-Chain-Triglyceride (MCT) oil, * Glycerin, ^ Propanediol (naturally derived preservative), * Vanilla Planifolia (vanilla) extract and Citric Acid (food grade preservative).

HOW TO USE HEMP OIL DROPS:

As a hemp oil supplement, take 1-3 times a day as desired. Place 7-10 drops under the tongue; hold for 60-90 seconds, then swallow.

Targets your skin’s needs and deeply penetrates to sore muscles & tissue.

Lightweight and fast-drying blend that you can use every day on non-sensitive areas on the entire body that is non-greasy, easy to apply without hands and does not stain clothing. This special blend of CBD, Menthol and Camphor uniquely provides excellent deep-freeze properties and may also slow the signs of aging by protecting a full range of telomeres. This will soon become a favorite in your daily care routine as deep penetration is performed without a greasy or sticky feeling. Our fast-acting CBD CryoGel infuses 99.9% pure CBD with 3.5% USP Menthol Crystals, Organic Camphor Extract, Organic Yerba Mate Extract, Organic Aloe Extract, Carbomer, Vitamin E, Alcohol, Triethanalamine FD&C Yellow #5 and FD&C Blue #5.

Instructions: Use it three or four times daily. Apply to affected areas and non-sensitive skin around pain, arthritis and swollen muscles. Some results may vary depending on your general health.

GMO-FREE CRUELTY-FREE PARABEN FREE

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Media Group (CannabisFN), owned and operated by CFN Enterprises Inc. (OTCQB: CNFN), is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading